Clinical Trials Using Panobinostat

Clinical trials are research studies that involve people. The clinical trials on this list are studying Panobinostat. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-6 of 6
  • Panobinostat in Treating Younger Patients with Diffuse Intrinsic Pontine Glioma

    This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma. Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 10 locations

  • A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

    The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
    Location: 9 locations

  • Panobinostat, Carfilzomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

    This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back or does not respond to treatment. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple myeloma cells from patients’ blood samples, the researchers will do laboratory tests to look at how well each of the drugs, alone and in different combinations, kill multiple myeloma cells. If the laboratory tests work well, they may be used in the future to help plan treatment for future patients.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan before Stem Cell Transplant in Treating Patients with Refractory or Relapsed Multiple Myeloma

    This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and melphalan before stem cell transplant work in treating patients with multiple myeloma that does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving high-dose chemotherapy, such as gemcitabine hydrochloride, busulfan, and melphalan, before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. Previously collected stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Panobinostat / Bortezomib / Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

    The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide exposure, safety and efficacy data to identify the optimal regimen of PAN in a randomized, 3-arm parallel design. This study will also assess the impact of administering s.c. BTZ (in combination with PAN and Dex) twice weekly for 4 cycles, and then weekly starting from Cycle 5 until disease progression in patients ≤ 75 years of age. Patients > 75 years of age will receive for the entire treatment period s.c. BTZ weekly (in combination with PAN and Dex) until disease progression. Patients will be treated until disease progression or until they discontinue earlier due to unacceptable toxicity or for other reasons. Patients who discontinued study treatment for reasons other than disease progression will be followed for efficacy every 6 weeks. All patients will be followed for survival until the last patient entering long-term follow-up has completed a 3 year survival follow-up or discontinued earlier.
    Location: See Clinical

  • Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

    This phase II trial studies how well panobinostat works in preventing graft-versus-host disease (GVHD) in patients with hematologic disorders (begins in blood-forming tissue, such as the bone marrow, or in cells of the immune system) undergoing donor stem cell transplant. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Panobinostat may help suppress the immune system (cells in the body that can cause GVHD), reduce the release of proteins (cytokines) that may contribute to inflammation in GVHD and increase production of cells (T regulatory cells) that can help to protect against GVHD.
    Location: Moffitt Cancer Center, Tampa, Florida